no title
Background: The knowledge base on new psychoactive substances (NPS) is generally limited. This introduces new challenges and increased unpredictability in substance abuse treatment.
Case presentation: A man in his thirties was submitted to detoxification after reportedly using flubromazolam, a high potency designer benzodiazepine, which he had purchased on the dark web. Extensive drug testing of serum, urine and hair, and the remains in a dropper bottle delivered by the patient, did not reveal flubromazolam or possible metabolites, but did reveal several common drugs of abuse, and 8-aminoclonazolam, a metabolite of clonazolam, another designer benzodiazepine sold on the dark web. The detoxification was uncomplicated. An excessive treatment protocol based on the patient's information, involving high preparedness and increased resources, both clinically and analytically, turned out to be unnecessary.
Interpretation: The drug use and clinical course in this case proved to be more common than the unit prepared for. The case history illustrates both the challenges with users of NPS and the general unpredictability in substance abuse treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke - 144(2024), 4 vom: 19. März |
| Sprache: |
Norwegisch |
|---|
| Weiterer Titel: |
Avrusning etter bruk av nye rusmidler fra internett |
|---|
| Beteiligte Personen: |
Frost, Joachim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12794-10-4 |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 21.03.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.4045/tidsskr.23.0668 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369956184 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369956184 | ||
| 003 | DE-627 | ||
| 005 | 20240322001118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||nor c | ||
| 024 | 7 | |a 10.4045/tidsskr.23.0668 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369956184 | ||
| 035 | |a (NLM)38506014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a nor | ||
| 100 | 1 | |a Frost, Joachim |e verfasserin |4 aut | |
| 246 | 3 | 3 | |a Avrusning etter bruk av nye rusmidler fra internett |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The knowledge base on new psychoactive substances (NPS) is generally limited. This introduces new challenges and increased unpredictability in substance abuse treatment | ||
| 520 | |a Case presentation: A man in his thirties was submitted to detoxification after reportedly using flubromazolam, a high potency designer benzodiazepine, which he had purchased on the dark web. Extensive drug testing of serum, urine and hair, and the remains in a dropper bottle delivered by the patient, did not reveal flubromazolam or possible metabolites, but did reveal several common drugs of abuse, and 8-aminoclonazolam, a metabolite of clonazolam, another designer benzodiazepine sold on the dark web. The detoxification was uncomplicated. An excessive treatment protocol based on the patient's information, involving high preparedness and increased resources, both clinically and analytically, turned out to be unnecessary | ||
| 520 | |a Interpretation: The drug use and clinical course in this case proved to be more common than the unit prepared for. The case history illustrates both the challenges with users of NPS and the general unpredictability in substance abuse treatment | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 650 | 7 | |a Designer Drugs |2 NLM | |
| 650 | 7 | |a Psychotropic Drugs |2 NLM | |
| 700 | 1 | |a Mikkelsen, Trine |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Malin Nordahl |e verfasserin |4 aut | |
| 700 | 1 | |a Bjerke, Hans Aleksander |e verfasserin |4 aut | |
| 700 | 1 | |a Gundersen, Per Ole M |e verfasserin |4 aut | |
| 700 | 1 | |a Aamo, Trond Oskar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke |d 1946 |g 144(2024), 4 vom: 19. März |w (DE-627)NLM00004475X |x 0807-7096 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2024 |g number:4 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4045/tidsskr.23.0668 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2024 |e 4 |b 19 |c 03 | ||